ASH 2023 – Regeneron defends its bispecifics
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
ASH 2023 – the markets forgive MorphoSys
Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.
ASH 2023 – sense and serendipity in Dizal's Jackpot win
Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.
ASH 2023 – a new EZ battle shapes up
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
